spacer
home > white papers > Speciality Logistics Outlook 2015 - World Courier
WHITE PAPERS
logo_World_Cour5.JPEG

World Courier

phone +44 (0)20 7928 7256
email marketing@worldcourier.com
web http://www.worldcourier.com
email 12th Floor, 25 Farringdon Street, London, EC4A4AB

Speciality Logistics Outlook 2015

To date, there are more than 178,000 registered clinical trials taking place across the globe, and global pharma’s volume has more than doubled over the last decade. With emerging markets showing explosive predictive growth through 2016, shippers and trial sponsors can expect continued regulatory and overall logistics complexities that foster demand for local, inmarket resources across the globe.
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Sanofi invests $180 million equity in Owkin’s artificial intelligence and federated learning to advance oncology pipeline

Sanofi announced today an equity investment of $180 million and a new strategic collaboration with Owkin comprised of discovery and development programmes in four exclusive types of cancer, with a total payment of $90 million for three years plus additional research milestone-based payments.
More info >>


White Papers

Six Strategies to Stretch Your Limited Drug Supply for Clinical Studies

PCI Pharma Services

Bringing a new drug to market can be a heavy financial burden on any pharmaceutical company. It has become even more burdensome over the last several years as the industry pushes the boundaries of innovation. This is because newer, often more-complex therapies not only increase risk in drug development but also drive costs even higher. A recent analysis of the investment needed to develop a new prescription medicine shows the total cost can be as high as $2.6 billion (1). That number becomes even more staggering when you consider the fact that only about 12 percent of drug candidates that make it to Phase I testing are eventually approved by the FDA (2). The investment companies lose as a result may be too devastating to their bottom line to ever recover.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement